TKT and cancer: To overcome this issue, Zhang et al. [83] designed a multifunctional chitosan-based nanoplatform (CEPH), which specifically targets EGFR-overexpressing cancer cells with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK inhibitor) and is loaded with a sonosensitizer, hematoporphyrin and perfluorooctyl bromide, an oxygen-storing agent, to locally deliver hematoporphyrin and oxygen to EGFR-overexpressing NSCLC cells.